NASDAQ:RXDX
Delisted
Prometheus Biosciences Inc Stock News
$199.92
+0 (+0%)
At Close: Sep 14, 2023
Merck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus deal
06:32am, Tuesday, 01'st Aug 2023
Shares of Merck are down roughly 4% this year, with a market value of roughly $270 billion, making it the third largest pharmaceutical company based in the U.S.
Prometheus Biosciences, Inc. (RXDX) is a Great Momentum Stock: Should You Buy?
01:42pm, Friday, 12'th May 2023
Does Prometheus Biosciences, Inc. (RXDX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue Estimates
07:07pm, Tuesday, 09'th May 2023
Prometheus Biosciences, Inc. (RXDX) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $0.82 per share a year ago.
Why Prometheus Biosciences Stock Is Skyrocketing This Week
04:24pm, Thursday, 20'th Apr 2023
Merck plans to acquire Prometheus for $10.8 billion in an all-cash deal. The deal will add Prometheus' lead candidate, immunology drug PRA023, to Merck's pipeline.
Why Merck Is Buying Prometheus Biosciences For About $10.8 Billion
01:13pm, Wednesday, 19'th Apr 2023
Merck (known as MSD outside the United States and Canada) and Prometheus Biosciences recently announced that the companies have entered into a definitive agreement under which Merck, through a subsidi
Prometheus Biosciences, Inc. (RXDX) Stock Jumps 69.7%: Will It Continue to Soar?
04:36am, Tuesday, 18'th Apr 2023
Prometheus Biosciences, Inc. (RXDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher
Wells Fargo's Mohit Bansal on Merck's $10.8B deal to buy Prometheus
05:55pm, Monday, 17'th Apr 2023
Mohit Bansal, Wells Fargo securities analyst, joins 'Closing Bell: Overtime' to discuss Merck's acquisition of Prometheus and Moderna's positive cancer therapy trial results.
Roivant Sciences shares spike on Merck-Prometheus Biosciences deal
12:23pm, Monday, 17'th Apr 2023
Roivant Sciences shares took off on the news that Merck is acquiring Prometheus Biosciences in a $10.8 billion deal as investors placed their bets on which of the two companies could be first to br
Merck's Prometheus Acquisition Is A Step In The Right Direction
12:09pm, Monday, 17'th Apr 2023
Merck is facing the LOE on Keytruda before the end of the decade, which makes up more than 35% of the company's revenue. The company has an impressive portfolio of assets, but its pipeline is sparse a
Why Shares of Prometheus Biosciences Are Soaring Monday
12:09pm, Monday, 17'th Apr 2023
Prometheus' lead therapy treats ulcerative colitis and a variety of autoimmune disorders. Merck is looking to supplement its immunology portfolio.
Biotech stock Prometheus Biosciences opened 70% up today: here's why
10:56am, Monday, 17'th Apr 2023
Prometheus Biosciences Inc (NASDAQ: RXDX) opened about 70% up on Monday after Merck & Co Inc (NYSE: MRK) said it will buy the biotechnology company for $10.8 billion.
Prometheus (RXDX) Stock Surges 70% on Buyout Offer From Merck
10:41am, Monday, 17'th Apr 2023
Prometheus (RXDX) is set to be acquired by Merck for $11 billion, adding Prometheus' lead product candidate, PRA023, to Merck's portfolio. Prometheus' stock is up 70%.
Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom
10:21am, Monday, 17'th Apr 2023
Merck is acquiring Prometheus Bio in a well-timed $10.8 billion deal ahead of Keytruda's patent loss. The news sent RXDX stock flying Monday.
Merck agrees to acquire Prometheus Biosciences
09:55am, Monday, 17'th Apr 2023
Yahoo Finance's Anjalee Khemlani joins the Live show to discuss news that Merck has agreed to acquire biotechnology company Prometheus Biosciences.
RXDX Stock Alert: The $10.8 Billion Reason Prometheus Biosciences Is Surging Today
09:50am, Monday, 17'th Apr 2023
Prometheus Biosciences (NASDAQ: RXDX ) stock surged almost 70% after agreeing to be bought by Merck (NYSE: MRK ) for $10.8 billion in cash. The agreement values Prometheus at $200 per share.